Evidence map›Paper›PMID 40847193›Full record

ArticleCommunications biology2025

3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer.

Sarah J Harmych, Thomas P Hasaka, Chelsie K Sievers, Seung Woo Kang, Marisol A Ramirez, Vivian Truong Jones, Zhiguo Zhao, Oleg Kovtun, Claudia C Wahoski, Qi Liu and 4 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah J HarmychDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-9967-5398
Thomas P HasakaVanderbilt Institute of Chemical Biology, High-Throughput Screening Facility, Vanderbilt University, Nashville, TN, USA.
Chelsie K SieversDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Seung Woo KangDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0009-0003-4328-5683
Marisol A RamirezDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Vivian Truong JonesDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Oleg KovtunDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-6809-9332
Claudia C WahoskiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Qi LiuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ken S LauDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-8438-0319
Robert J CoffeyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-2180-3844
Joshua A BauerVanderbilt Institute of Chemical Biology, High-Throughput Screening Facility, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-8019-900X
Bhuminder SinghDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. bhuminder.singh@vumc.org.ORCID http://orcid.org/0000-0003-1357-2158

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Integrated approach to study early and late events in colonic neoplasia: mouse to manR35CA197570 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2017 to 2026
$9.4M
A Multimodal 3D Atlas of Colorectal Cancer Across Ages of OnsetU01CA294527 · NCI · VANDERBILT UNIVERSITY · PI LAU, KEN S, SPRAGGINS, JEFFREY M · 2024 to 2025
$5.2M
Tuft cell heterogeneity in function, lineage, and structure in ileal inflammatory diseaseR01DK103831 · NIDDK · VANDERBILT UNIVERSITY · PI LAU, KEN S · 2016 to 2024
$4.4M
Role of Receptor Tyrosine Kinase cross-talk in colorectal cancerR01CA248505 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SINGH, BHUMINDER · 2021 to 2025
$2.2M
Cancer Pharmacologist and HTS ScientistR50CA211206 · NCI · VANDERBILT UNIVERSITY · PI Joshua A. Bauer · 2016 to 2026
$1.8M
Integrated ImageXpress Micro Confocal High Content Screening SystemS10OD028719 · OD · VANDERBILT UNIVERSITY · PI BAUER, JOSHUA A. · 2021 to 2021
$799k
Automated Compound Storage and Retrieval SystemS10OD028715 · OD · VANDERBILT UNIVERSITY · PI BAUER, JOSHUA A. · 2022 to 2022
$741k
NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA248505NCI NIH HHS R35 CA197570NCI NIH HHS R50 CA211206NCI NIH HHS U01 CA294527NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK103831NIGMS NIH HHS T32 GM007628NIH HHS S10 OD028715NIH HHS S10 OD028719U.S. Department of Health & Human Services | National Institutes of Health (NIH) S10OD028715U.S. Department of Health & Human Services | National Institutes of Health (NIH) S10OD028719U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32GM07628U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50 236733U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R50CA211206U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA294527U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK103831
6 · The paper itself

Abstract

Loss of polarity is a hallmark of cancer, and the related epithelial-to-mesenchymal transition (EMT) phenotype impacts prognosis and therapy outcomes, particularly in colorectal cancer (CRC). However, the mechanisms and drugs that impact EMT-related morphological changes are understudied, due to the complete failure of typical live/dead 2D high-throughput screens to capture morphology or the lack of robustness of 3D screens. We designed a high-throughput screen using 3D type I collagen cultures of CRC cells to assess morphological changes in colonies and identified several FDA-approved drugs that re-epithelialize CRC colonies. One of these drugs, azithromycin, increased colony circularity, enhanced E-cadherin membrane localization and ZO-1 localization to tight junctions, caused transcriptomic changes consistent with downregulation of EMT, and elevated sensitivity to the chemotherapeutic, irinotecan. A retrospective analysis of patient data demonstrated that the use of azithromycin in patients undergoing treatment for CRC with irinotecan had improved the 5 year survival compared to the chemotherapy alone. These results highlight the importance of morphological screens to identify novel drug candidates and synergistic mechanisms.

Indexed as

Antineoplastic AgentsCell PolarityCollagenColorectal NeoplasmsHigh-Throughput Screening AssaysAzithromycinCell Line, TumorEpithelial-Mesenchymal TransitionHumansIrinotecanAntineoplastic AgentsAzithromycinCollagenIrinotecan

Identifiers

PMID40847193
PMCPMC12373842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.